10-K: Cocrystal Pharma Reports Annual Results, Faces Going Concern Uncertainty Amidst Antiviral Development

Cocrystal Pharma's annual report reveals ongoing antiviral therapeutic development efforts alongside financial challenges and a going concern qualification.

Summary

• Cocrystal Pharma, a clinical-stage biotechnology company, is focused on discovering and developing novel antiviral therapeutics.
• The company's research and development efforts primarily target influenza, norovirus, and coronaviruses.
• Key programs include CC-42344 for influenza A, and CDI-988 as a pan-viral treatment for noroviruses and coronaviruses.
• A Phase 2a human challenge study with oral CC-42344 is underway, but enrollment was extended due to low influenza infection rates among study participants.
• Oral CDI-988 is being clinically evaluated in a Phase 1 study in Australia, with favorable safety and tolerability results reported from single-ascending dose cohorts.
• The company reported a net loss of $17.504 million for the year ended December 31, 2024, compared to a net loss of $17.984 million for the year ended December 31, 2023.
• Research and development expenses were $12.537 million for 2024, a decrease from $15.169 million in 2023.
• The company's auditor has raised substantial doubt about its ability to continue as a going concern.
• Cocrystal Pharma needs to raise additional capital to fund its operations and research and development programs.
• The company is pursuing strategic alliances for research and development programs.
• The company employed 11 full-time employees as of December 31, 2024.
• The company's common stock is traded on The Nasdaq Capital Market under the symbol COCP.

Sentiment

Score: 3

Explanation: The document presents a mixed picture. While there is progress in the development of antiviral candidates, the financial situation and going concern qualification raise significant concerns. The delay in the Phase 2a study is also a negative factor.

Positives

• CC-42344 has shown excellent in vitro antiviral activity against influenza A strains, including avian pandemic strains and Tamiflu and Xofluza resistant strains.
• CDI-988 was specifically designed and developed as a broad-spectrum antiviral inhibitor to a highly conserved region in the active site of noroviruses, coronaviruses and other 3CL viral proteases.
• The company's Phase 1 study with CDI-988 has shown favorable safety and tolerability results from the single-ascending dose cohorts.
• The company successfully appealed a legal judgement and received a $1.6 million refund.

Negatives

• The company's auditor has raised substantial doubt about its ability to continue as a going concern.
• The company has limited capital and substantial accumulated deficit as of the date of this Report.
• The company does not have sufficient working capital and cash flows for continued operations for at least the next 12 months.
• The company's Phase 2a study with oral CC-42344 has been extended due to unexpectedly low influenza infection among study participants.
• The company reported a net loss of $17.504 million for the year ended December 31, 2024.

Risks

• The company's financial statements are qualified on a going concern basis.
• The company has had a history of losses and may not generate sustained positive cash flow sufficient to fund its operations and research and development programs.
• The company needs to obtain additional financing when needed on favorable terms, or at all.
• There are delays or complications in conducting clinical trials, such as the Phase 2a study for oral CC-42344 for the Influenza program which in late 2024 was determined must be extended due to an insufficient infection rate.
• There are risks related to the company's development efforts, including the risk that clinical studies may not yield favorable results, or that earlier clinical results of effectiveness and safety may not be adequate, reproducible or indicative of future results.
• There is increased competition, including the possibility that competitors may develop effective and/or less costly treatments or vaccines, including as part of the programs financed by the U.S. government.
• The information technology systems that the company relies on may be subject to unauthorized tampering, cyberattack or other data security or privacy incidents that could impact billing processes or disrupt operations.
• There is a failure to maintain the security of patient-related information.
• The company's ability to use its net operating loss carry forwards and certain other tax attributes may be limited.

Future Outlook

The company expects to continue incurring substantial operating losses and negative cash flows from operations over the next several years during its pre-clinical and clinical development phases and needs to complete a financing to provide the needed working capital.

Management Comments

• Management determined that an extension of the Phase 2a study is necessary due to low infectivity rate of the challenge influenza strain used in this study.
• Management concluded that our disclosure controls and procedures were effective as of December 31, 2024.
• Management concluded that our internal control over financial reporting was effective as of December 31, 2024.

Industry Context

The biotechnology and pharmaceutical industries are subject to intense and rapidly changing competition as companies seek to develop new technologies and proprietary products. The company faces worldwide competition from larger biotechnology and pharmaceutical companies, universities and other academic or research institutions and government agencies that are developing and commercializing pharmaceutical products similar to our product candidates that target the viruses we are seeking to treat.

Comparison to Industry Standards

• The document mentions several competitors, including Roche, Gilead Sciences, Inc., Merck, Janssen Pharmaceuticals, Inc., Bristol-Myers Squibb, Toyama Chemical Co., Shionogi/Roche and Abbvie, Inc.
• The document notes that many of these companies have substantially greater financial resources, expertise, and capabilities than Cocrystal Pharma.
• The document also mentions that at least four treatments and five vaccines for COVID-19 have received FDA approval, highlighting the competitive landscape in that therapeutic area.
• The document states that no competing company has yet developed a short HCV treatment of less than 8 weeks with a high (>95%) sustained virologic response (SVR) at week 12, which is a goal of Cocrystal Pharma's HCV program.

Corporate Governance

Legal Proceedings

• Liberty Insurance Underwriters Inc. filed suit against us in federal court in Delaware seeking a declaratory judgment that there was no insurance coverage for any settlement, judgment, or defense costs in the class and derivative litigation, that the monies totaling approximately $1 million it paid to the Company in connection with the SEC investigation were not covered by insurance, and for recoupment of the monies already paid.
• On March 29, 2023, the Third Circuit ruled in favor of the Company on the appeal, thereby vacating the trial courts prior grant of summary judgment in favor of Liberty.
• On November 16, 2023, prior to commencement of a new trial which had been scheduled for December 4, 2023, the parties entered into a settlement agreement pursuant to which Liberty paid the Company an additional $ 1 million and each party released the other from its respective claims and rights arising from the matter.

Related Party Transactions

• On August 14, 2024, the Company entered into a three-year lease extension with a limited liability company controlled by Dr. Phillip Frost, a director and a principal stockholder of the Company.
• On April 4, 2023, the Company entered into a Securities Purchase Agreement with two accredited investors including Frost Gamma Investments Trust, a trust in which Phillip Frost, M.D., a director of the Company, is the trustee whereby each purchaser purchased 1,015,229 shares of common stock at a price of $1.97 per share, or two equal $2,000,000 investments.
• The second purchaser was Fred Hassan, who several weeks later was appointed a director of the Company.

Stakeholder Impact

• Shareholders face the risk of dilution from future equity issuances.
• Employees face uncertainty due to the company's going concern qualification and potential need to curtail operations.
• The company's ability to develop and commercialize antiviral therapies could benefit patients and healthcare providers.
• The company's reliance on third-party manufacturers and CROs exposes it to supply chain and operational risks.

Next Steps

• The company is continuing discussions with the clinical research organization to address the Phase 2a study and determine a course forward.
• The company expects that the oral CDI-988 Phase 1 data will support future norovirus and coronavirus Phase 2 and Phase 3 studies.
• The topline data of the MAD cohorts, including based on an additional cohort with a higher dose of 1200 mg and a shorter treatment duration of five consecutive days, is expected to be released in the first half of 2025.
• The company needs to complete a financing to provide the needed working capital.

Key Dates

Keywords

antiviral, influenza, coronavirus, norovirus, CC-42344, CDI-988, clinical trials, biotechnology, pharmaceutical, research and development